Compare Becton Dickinson and Co (BDX) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Modine Manufacturing Company — how do they compare? Becton Dickinson and Co trades at $155.38 (market cap $41.51B), while Modine Manufacturing Company trades at $231.46 (market cap $12.19B). The key difference: Becton Dickinson and Co is far larger — about 3.4× Modine Manufacturing Company's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals.
| BDX | MOD | |
|---|---|---|
Market Cap | $41.51B | $12.19B |
Sector | Health | Technology |
52-Week High | $185.39 | $306.89 |
52-Week Low | $135.49 | $90.02 |
Enterprise Value | $57.97B | $12.55B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Modine (MOD) is trading at $234.28, down 4.73% amid bearish technical signals, though it maintains strong analyst support with a $328.80 consensus price target. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.71 exceeding estimates by 10%. Fundamentals show revenue growth to $2.58 billion in 2025 but declining net margins, while the stock trades at elevated valuation multiples including a P/E of 101.58.
The outlook remains positive based on analyst consensus and recent executive appointments, but risks include high valuation, margin pressure, and technical weakness. Investment opportunity lies in the 40% upside to price targets if execution continues, though investors face volatility from supply chain challenges and competitive pressures in the thermal management sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
